Polymerase in Biological Technology
Navigation Links
Polymerase in Biological Technology
... as well as representative HCV protease and polymerase inhibitors. Furthermore, ANA598 retains full ... resistance to protease inhibitors, nucleoside polymerase inhibitors and non-nucleoside polymerase inhibitors that act at binding sites distinct ...
... data on IDX184, a once-daily, oral nucleotide polymerase inhibitor prodrug currently being evaluated in a ... two clinical candidates: IDX375, a non-nucleoside polymerase inhibitor and IDX316, a protease inhibitor, both ... therapy." IDX184 Nucleotide Prodrug polymerase Inhibitor IDX184 is a liver-targeted, oral ...
... ITMN-191 (R7227) in combination with nucleoside polymerase inhibitor R7128 (Roche/Pharmasset), referred to ... (ITMN-191), a protease inhibitor, and R7128, a polymerase inhibitor, in 14 days of combination therapy. ... Pharmasset, Roche is developing R7128, an HCV RNA polymerase inhibitor, also for therapy in combination with ...
... ACTIVITY OF THE LIVER-TARGETED NUCLEOTIDE HCV polymerase INHIBITOR IDX184 CORRELATES WITH TROUGH SERUM ... IDX184, A LIVER-TARGETED NUCLEOTIDE HCV polymerase INHIBITOR: RESULTS OF A FIRST-IN-MAN SAFETY AND ... OF IDX375, A NOVEL AND POTENT NON-NUCLEOSIDE HCV polymerase INHIBITOR - Abstract #1442; Poster ...
... investigational hepatitis C non-nucleoside polymerase inhibitor. Anadys is currently enrolling ... review of ANA598, one of the few non-nucleoside polymerase inhibitors in clinical development for the ... complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist ...
... abstract from the clinical study of ITMN-191 (R7227) in combination with polymerase inhibitor R7128 (Roche/Pharmasset), referred to as the INFORM-1 study, has ... First-in-man Demonstration of Potent Antiviral Activity with a Nucleoside polymerase Inhibitor (R7128) and Protease (R7227/ITMN-191) Inhibitor Combination in ...
... SmartChip system's ability to generate real-time polymerase chain reaction (PCR) results in clinical samples for approximately 1,000 ... as the first whole genome, high throughput gene expression real-time polymerase chain reaction (PCR) platform. This innovative system, combined with ...
... and reconstitution of primers for rapid high-throughput 100 nL real-time polymerase chain reaction (PCR). Additionally, the platform's ability to perform PCR ... as the first whole genome, high throughput gene expression real-time polymerase chain reaction (PCR) platform. This innovative system, combined with ...
... who had failed prior interferon-based therapy. R7128, an HCV nucleoside polymerase inhibitor, may provide better antiviral activity in these patients where the protease inhibitors and non-nucleoside polymerase inhibitors have not yet shown success. Longer-term studies of R7128 with ...
... a.m. (PST) on Friday, March 28, will celebrate the 25th anniversary of polymerase chain reaction (PCR) and discuss the future of revolutionary technology. ... as the first whole genome, high throughput gene expression real-time polymerase chain reaction (PCR) platform and promises to deliver significant speed ...
... R7128, a prodrug of PSI-6130, is an oral cytidine nucleoside analog polymerase inhibitor of HCV that is being developed through Pharmasset's ... Safety, and Tolerability of R7128, a Novel Nucleoside polymerase Inhibitor for HCV Following Single, Ascending Oral Doses in Healthy ...
... "Disrupting the interaction between NS4B and HCV-RNA may be a promising new method to treat HCV infection and help combat drug resistance to HCV polymerase and protease inhibitors. We are rapidly advancing novel small molecule inhibitors of NS4B-RNA binding into the clinic for the benefit of clinicians ...
... Real-Time PCR System The SmartChip Real-Time PCR System(TM) is designed as the first whole genome, high-throughput gene expression real-time polymerase chain reaction (PCR) platform. WaferGen believes the SmartChip Real-Time PCR System will be the first platform to combine the high-throughput ...
... improvements in treatment outcomes may be attainable with the introduction of new medicines. The Company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C. The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous ...
... an extensive test menu of prognostic and predictive molecular oncology biomarkers using fluorescence in situ hybridization (FISH), flow cytometry, polymerase chain reaction (PCR) and other cutting-edge technologies. For further information please visit www.exiqondiagnostics.com . About Exiqon ...
... for the diagnosis of Clostridium difficile infections Dr. Jim Gray, Senior Microbiologist, Birmingham Children's Hospital: Experience with polymerase chain reaction-based methicillin-resistant Staphylococcus aureus screening in paediatrics Dr. Paolo Cavallerio, Ospedale Molinette, Torino, ...
... for the gene expression and genotyping markets. SmartChip is being developed as the first whole genome, high throughput gene expression real-time polymerase chain reaction (PCR) platform. This innovative system, combined with next-generation chemistry and optimized assays being developed by WaferGen, ...
... posters to be presented at EASL are as follows: Combination of the NS3/4A Protease Inhibitor ITMN-191 with the Allosteric NS5B polymerase Inhibitor ITMN-8020 Enhances Replicon Clearance and Reduces the Emergence of Drug Resistant Variants . Discovery of Potent, Bioavailable ...
Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
... ANA598 is an investigational oral non-nucleoside polymerase inhibitor that Anadys is developing for the ... Activity of ANA598, a Potent Non-Nucleoside polymerase Inhibitor, In Chronic Hepatitis C Patients," at ... protease inhibitor telaprevir and the nucleoside polymerase inhibitor PSI-6130 are synergistic. These ...... data on IDX184, a once-daily, oral nucleotide polymerase inhibitor prodrug currently being evaluated in a ... two clinical candidates: IDX375, a non-nucleoside polymerase inhibitor and IDX316, a protease inhibitor, both ... therapy." IDX184 Nucleotide Prodrug polymerase Inhibitor IDX184 is a liver-targeted, oral ...
... ITMN-191 (R7227) in combination with nucleoside polymerase inhibitor R7128 (Roche/Pharmasset), referred to ... (ITMN-191), a protease inhibitor, and R7128, a polymerase inhibitor, in 14 days of combination therapy. ... Pharmasset, Roche is developing R7128, an HCV RNA polymerase inhibitor, also for therapy in combination with ...
... ACTIVITY OF THE LIVER-TARGETED NUCLEOTIDE HCV polymerase INHIBITOR IDX184 CORRELATES WITH TROUGH SERUM ... IDX184, A LIVER-TARGETED NUCLEOTIDE HCV polymerase INHIBITOR: RESULTS OF A FIRST-IN-MAN SAFETY AND ... OF IDX375, A NOVEL AND POTENT NON-NUCLEOSIDE HCV polymerase INHIBITOR - Abstract #1442; Poster ...
... investigational hepatitis C non-nucleoside polymerase inhibitor. Anadys is currently enrolling ... review of ANA598, one of the few non-nucleoside polymerase inhibitors in clinical development for the ... complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist ...
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
... Results of in-vitro study of ITMN-191 with Roche polymerase inhibitors - BRISBANE, Calif., Sept. 24 ... of ITMN-191 in combination with two separate HCV polymerase inhibitors in the Roche portfolio suggest the ... #1885): ITMN-191 was combined separately with two polymerase inhibitors, R7128 (Roche/Pharmasset) and R1626 ...Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
... evaluation of ANA598, our non-nucleoside polymerase inhibitor for the treatment of hepatitis C, ... including protease inhibitors and nucleoside polymerase inhibitors. -- ANA773. Anadys presented data on ... non- nucleoside inhibitor of the NS5b polymerase for the treatment of chronic hepatitis C, and ...Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
... ANA598 ANA598 is the Company's non-nucleoside HCV polymerase inhibitor. Finalization of ANA598 Phase II Protocol. Anadys has ... of new medicines. The Company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C. The Company has also ...Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
... IND- or CTA-enabling preclinical studies for IDX375, a non-nucleoside polymerase inhibitor, and is preparing documentation to support initial regulatory ... plan to file investigational new drug applications from our non-nucleoside polymerase inhibitor and protease inhibitor programs. These efforts will take us ...MIT, BU engineer cellular circuits that count events
... into the cell the cell produces the first protein in the sequence, an RNA polymerase (an enzyme that controls transcription of another gene). During the second influx, the first RNA polymerase initiates production of the second protein, a different RNA polymerase. ...InterMune Reports First Quarter 2009 Financial Results and Business Highlights
... new data from INFORM-1, the first-ever combination of a nucleoside polymerase inhibitor and protease inhibitor in the absence of interferon in patients ... INFORM-1 clinical trial evaluating ITMN-191 in combination with nucleoside polymerase inhibitor R7128 but no interferon or ribavirin in patients with HCV ...Idenix Pharmaceuticals Reports First Quarter Financial Results
... its three HCV discovery and development programs, with a nucleoside/tide polymerase inhibitor being evaluated in a proof-of-concept clinical study and non-nucleoside polymerase and protease inhibitors undergoing late-stage preclinical testing. ...... abstract from the clinical study of ITMN-191 (R7227) in combination with polymerase inhibitor R7128 (Roche/Pharmasset), referred to as the INFORM-1 study, has ... First-in-man Demonstration of Potent Antiviral Activity with a Nucleoside polymerase Inhibitor (R7128) and Protease (R7227/ITMN-191) Inhibitor Combination in ...
... SmartChip system's ability to generate real-time polymerase chain reaction (PCR) results in clinical samples for approximately 1,000 ... as the first whole genome, high throughput gene expression real-time polymerase chain reaction (PCR) platform. This innovative system, combined with ...
Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
... a phase I, healthy volunteer study of IDX184, its lead nucleotide polymerase inhibitor for the treatment of hepatitis C, and advanced the drug ... continued IND-enabling preclinical studies for its lead HCV non-nucleoside polymerase inhibitor and HCV protease inhibitor programs. "Idenix ...... and reconstitution of primers for rapid high-throughput 100 nL real-time polymerase chain reaction (PCR). Additionally, the platform's ability to perform PCR ... as the first whole genome, high throughput gene expression real-time polymerase chain reaction (PCR) platform. This innovative system, combined with ...
J. Craig Venter Institute Researchers Publish Significant Advance in Genome Assembly Technology
... available DNA (known as oligonucleotides) and using an adaptation of polymerase chain reaction (PCR), known as polymerase cycle assembly (PCA), to build the phi X genome. The team produced the ...Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
... Phase Ib clinical trial of ANA598, an investigational oral non-nucleoside polymerase inhibitor for the treatment of hepatitis C virus (HCV) infection, and ... developing two potentially complementary agents, ANA598, a non- nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also ...... who had failed prior interferon-based therapy. R7128, an HCV nucleoside polymerase inhibitor, may provide better antiviral activity in these patients where the protease inhibitors and non-nucleoside polymerase inhibitors have not yet shown success. Longer-term studies of R7128 with ...
Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
... candidates from both its HCV protease inhibitor and non-nucleoside polymerase inhibitor programs are entering IND-enabling preclinical studies. "This ... drug candidates from each of the major HCV drug classes, nucleoside/tide polymerase inhibitors, non-nucleoside polymerase inhibitors and protease ...... a.m. (PST) on Friday, March 28, will celebrate the 25th anniversary of polymerase chain reaction (PCR) and discuss the future of revolutionary technology. ... as the first whole genome, high throughput gene expression real-time polymerase chain reaction (PCR) platform and promises to deliver significant speed ...
Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
... of ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B polymerase for the treatment of HCV, and ANA773, an oral TLR7 agonist prodrug for ... developing ANA598, a small-molecule, non- nucleoside inhibitor of the NS5B polymerase for the treatment of HCV and ANA773, an oral TLR7 agonist prodrug for ...... R7128, a prodrug of PSI-6130, is an oral cytidine nucleoside analog polymerase inhibitor of HCV that is being developed through Pharmasset's ... Safety, and Tolerability of R7128, a Novel Nucleoside polymerase Inhibitor for HCV Following Single, Ascending Oral Doses in Healthy ...
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
... Roche and Pharmasset, Inc. reported initial results from the novel Phase 1 INFORM-1 clinical trial evaluating ITMN-191 in combination with nucleoside polymerase inhibitor R7128, but no interferon or ribavirin, in patients with HCV infection. Data from the first four dosage cohorts of the study demonstrated ...Pharmasset to Present at Canaccord Adams Conference
... (HIV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase thus inhibiting viral replication. We currently have three clinical-stage product candidates: RG7128, a nucleoside analog for chronic HCV infections, ...... "Disrupting the interaction between NS4B and HCV-RNA may be a promising new method to treat HCV infection and help combat drug resistance to HCV polymerase and protease inhibitors. We are rapidly advancing novel small molecule inhibitors of NS4B-RNA binding into the clinic for the benefit of clinicians ...
Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
... improvements in treatment outcomes may be attainable with the introduction of new medicines. The Company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C. The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous ...... Real-Time PCR System The SmartChip Real-Time PCR System(TM) is designed as the first whole genome, high-throughput gene expression real-time polymerase chain reaction (PCR) platform. WaferGen believes the SmartChip Real-Time PCR System will be the first platform to combine the high-throughput ...
... improvements in treatment outcomes may be attainable with the introduction of new medicines. The Company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C. The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous ...
... an extensive test menu of prognostic and predictive molecular oncology biomarkers using fluorescence in situ hybridization (FISH), flow cytometry, polymerase chain reaction (PCR) and other cutting-edge technologies. For further information please visit www.exiqondiagnostics.com . About Exiqon ...
A New Era in the Application of Lab-on-a-Chip to Rapid Point-of-Care Diagnosis
... The VDS technology has an advantage of not requiring the use of specialized equipment; VetDetect utilizes real-time reverse transcriptase polymerase chain reaction (RT-PCR) and VetScreen employs the conventional gel-based RT-PCR technique. All three platforms are highly sensitive and specific, ...A Global View: NanoLogix Creates Science Advisory Board
... holds a doctorate in the fields of biochemistry and molecular biology. He is an internationally respected expert in the new field of Real Time polymerase Chain Reaction and is president of his own firm, Fluoresentric, Inc. He brings to the advisory board an extensive insight into the links of ...... for the diagnosis of Clostridium difficile infections Dr. Jim Gray, Senior Microbiologist, Birmingham Children's Hospital: Experience with polymerase chain reaction-based methicillin-resistant Staphylococcus aureus screening in paediatrics Dr. Paolo Cavallerio, Ospedale Molinette, Torino, ...
Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
... C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral inducer of endogenous interferons that acts via the TLR7 pathway. The Company is also developing ANA773 for the ...Roche to Introduce New LightCycler(R) MRSA Advanced Test in the EU
... on Roche's LightCycler(R) 2.0 Instrument with nasal swab specimens from patients suspected of colonization, using Roche's patented real-time polymerase chain reaction (PCR) technology. Provided in a convenient, ready-to-use format, and designed for flexible batch sizes, the LightCycler(R) MRSA ...Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
... C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral inducer of endogenous interferons that acts via the TLR7 pathway. The Company is also developing ANA773 for the ...Genomic Study Shows Organic Skin Care Product Activates Key Anti-Aging Gene
... shows that Ambra-Lift™ stimulates Sirtuin-1 by using one of the latest genomic testing tools available. It's called quantitative real time polymerase Chain Reaction (PCR) and is able to imeasure genes turned "on" or "off" by skin care products like Ambra-Lift™. The ...... for the gene expression and genotyping markets. SmartChip is being developed as the first whole genome, high throughput gene expression real-time polymerase chain reaction (PCR) platform. This innovative system, combined with next-generation chemistry and optimized assays being developed by WaferGen, ...
... posters to be presented at EASL are as follows: Combination of the NS3/4A Protease Inhibitor ITMN-191 with the Allosteric NS5B polymerase Inhibitor ITMN-8020 Enhances Replicon Clearance and Reduces the Emergence of Drug Resistant Variants . Discovery of Potent, Bioavailable ...
Other Contentsparentingparentingadenomaadenomaadenomaparaplegiaparonychiaparenteralparenteralparenteralparesisparesthesia
Breaking Biology News(10 mins):MSU research may lead to new ways to control honeybee parasite 2Germany starts its part in the International Cancer Genome Project 2Germany starts its part in the International Cancer Genome Project 3Germany starts its part in the International Cancer Genome Project 4MythBusters 3A Dishing Up Food Safety Fact From Fiction 55438 1MythBusters 3A Dishing Up Food Safety Fact From Fiction 55438 2MythBusters 3A Dishing Up Food Safety Fact From Fiction 55438 3AutoGenomics Invited to Present at Thomas Weisel Partners 2009 Healthcare Conference 13703 1Alexza Stockholders Approve Share Issuance to Symphony Capital and Alexza Completes Acquisition of Symphony Allegro 13698 1Alexza Stockholders Approve Share Issuance to Symphony Capital and Alexza Completes Acquisition of Symphony Allegro 13698 2Alexza Stockholders Approve Share Issuance to Symphony Capital and Alexza Completes Acquisition of Symphony Allegro 13698 3Alexza Stockholders Approve Share Issuance to Symphony Capital and Alexza Completes Acquisition of Symphony Allegro 13698 4
Breaking Medicine News(10 mins):Health News:www.RightMedicare.com Launches to Offer Non-Biased Medicare Enrollment Assistance 2Health News:The Concord Grape Commands Attention at Major Scientific Conference 2Health News:The Concord Grape Commands Attention at Major Scientific Conference 3Health News:The Concord Grape Commands Attention at Major Scientific Conference 4Health News:The Concord Grape Commands Attention at Major Scientific Conference 5Health News:This Holiday Season Give the Gift of Good Health to Your Favorite Dog 2Health News:Nerve-cell transplants help brain-damaged rats fully recover lost ability to learn 2Health News:Nerve-cell transplants help brain-damaged rats fully recover lost ability to learn 3Health News:General Mills to Cut Sugar in Kids' Cereals 2
Other TagsClearClearClearClearClearClearModificationMenopauseWomenWomenWomenWomenSeveralNaturally[0] www.RightMedicare.com Launches to Offer Non-Biased Medicare Enrollment Assistance[1] The Concord Grape Commands Attention at Major Scientific Conference[0] This Holiday Season Give the Gift of Good Health to Your Favorite Dog[0] Nerve-cell transplants help brain-damaged rats fully recover lost ability to learn[1] General Mills to Cut Sugar in Kids' Cereals
GeckosClearModificationVineyardDiggingUnweavingMenopauseNewfoundWomenSqueezingSeveralNaturallyBleachVirulizin
Other Tagswiden 2demonstrates 2demonstrates 3demonstrates 4demonstrates 5demonstrates 6demonstrates 7demonstrates 8demonstrates 9bees 2code 2code 3code 4code 5code 6code 7code 8olfactory 2olfactory 3data 2data 3data 4data 5data 6data 7data 8data 9data 10| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |